Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Pozelimab and Cemdisiran Combination in Healthy Volunteers
NCT04601844Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Jul 2021
- Modality
- Antisense DNA, Recombinant Proteins and Enzymes, Conjugated siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of pozelimab and cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH) (3 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment emergent adverse events at 20 weeks. Started Nov 2020; status: completed.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04601844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601844.